Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anterix Inc.ATEX · Entity 4597 | Director · Executive Chairman | December 16, 2024 | December 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anterix Inc.
Report date December 16, 2024 · Filed December 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,973 |
Reported balance
After 2024-12-16 transaction · row 1
1 source rowRow 1 · 2024-12-16 · Sale · Disposed 13,609 · Balance 23,973 F1: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $33.34 to $33.55. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $33.34 to $33.55. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 21, 2020 Filed Dec 23, 2020 18:13 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 31,667 | $40.17 | $1,272,063.39 |
DisclosureSEC source: 0001209191-20-065071 · doc4.xml · nonDerivative · entry 2 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,250 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $40.00 to $40.81. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 18:13 UTC | Anterix Inc. ATEX · Entity 4597 | Exercise / conversionCommon Stock | 31,667 | $20.00 | $633,340.00 |
DisclosureSEC source: 0001209191-20-065071 · doc4.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2020 Filed May 3, 2021 20:50 UTC | Anterix Inc. ATEX · Entity 4597 | GiftCommon Stock | 12,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029650 · doc5.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,050 F1 · kind: These transactions represent gifts or charitable contributions by the Reporting Person. Read SEC document |
| September 08, 2020 Filed Sep 8, 2020 18:14 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 4,635 | $40.18 | $186,225.49 |
DisclosureSEC source: 0001209191-20-049778 · doc4.xml · nonDerivative · entry 3 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,250 F2 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the partial vesting and settlement of restricted stock units granted August 2018 and February 2020. F4 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $39.92 to $40.85. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 04, 2020 Filed Sep 8, 2020 18:14 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 9,715 | $42.30 | $410,916.33 |
DisclosureSEC source: 0001209191-20-049778 · doc4.xml · nonDerivative · entry 2 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,885 F2 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the partial vesting and settlement of restricted stock units granted August 2018 and February 2020. F3 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $42.00 to $42.63. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 18:14 UTC | Anterix Inc. ATEX · Entity 4597 | GrantStock Option (Right to Buy) · Derivative | 26,464 | $0.00 Strike: $46.85 | $0.00 |
DisclosureSEC source: 0001209191-20-049778 · doc4.xml · derivative · entry 4 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,464 Underlying: Common Stock · 26,464 shares Expires 2025-08-29 F5 · balance_after: On February 28, 2020, the Reporting Person was granted a performance-based stock option, which vests in two tranches upon the Issuer achieving certain performance milestones prior to December 30, 2020. The Compensation Committee determined that the performance milestone for the first tranche was satisfied, resulting in the vesting of the reported shares of common stock under the stock option. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 18:14 UTC | Anterix Inc. ATEX · Entity 4597 | GrantCommon Stock | 26,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-049778 · doc4.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,600 F1 · shares: On February 28, 2020, the Reporting Person was granted a performance-based restricted stock unit award (the "RSU"), which vests in two tranches upon the Issuer achieving certain performance milestones prior to December 30, 2020. The Compensation Committee determined that the performance milestone for the first tranche was satisfied, resulting in the vesting of the reported shares of common stock under the RSU. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:23 UTC | Anterix Inc. ATEX · Entity 4597 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,030 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047649 · doc4.xml · derivative · entry 3 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 3,030 shares Expires 2024-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option shares are fully vested. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:23 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 3,030 | $44.76 | $135,625.83 |
DisclosureSEC source: 0001209191-20-047649 · doc4.xml · nonDerivative · entry 2 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,591 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and includes the sale of shares in order to cover tax liabilities in connection with the exercise of stock options. F2 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $44.52 to $45.11. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 20:23 UTC | Anterix Inc. ATEX · Entity 4597 | Exercise / conversionCommon Stock | 3,030 | $20.00 | $60,600.00 |
DisclosureSEC source: 0001209191-20-047649 · doc4.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 19:06 UTC | Anterix Inc. ATEX · Entity 4597 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,162 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-20-046988 · doc4.xml · derivative · entry 9 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,030 Underlying: Common Stock · 8,162 shares Expires 2024-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option shares are fully vested. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 19:06 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 8,162 | $44.69 | $364,735.29 |
DisclosureSEC source: 0001209191-20-046988 · doc4.xml · nonDerivative · entry 7 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,591 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and includes the sale of shares in order to cover tax liabilities in connection with the vesting of restricted stock units and the exercise of stock options. F6 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $44.28 to $45.19. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 19:06 UTC | Anterix Inc. ATEX · Entity 4597 | Exercise / conversionCommon Stock | 8,162 | $20.00 | $163,240.00 |
DisclosureSEC source: 0001209191-20-046988 · doc4.xml · nonDerivative · entry 6 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 19:06 UTC | Anterix Inc. ATEX · Entity 4597 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,808 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-20-046988 · doc4.xml · derivative · entry 8 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,192 Underlying: Common Stock · 8,808 shares Expires 2024-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option shares are fully vested. Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 19:06 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 2,775 | $45.21 | $125,460.53 |
DisclosureSEC source: 0001209191-20-046988 · doc4.xml · nonDerivative · entry 5 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,591 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and includes the sale of shares in order to cover tax liabilities in connection with the vesting of restricted stock units and the exercise of stock options. F5 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $45.00 to $45.48. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 19:06 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 6,572 | $44.49 | $292,401.42 |
DisclosureSEC source: 0001209191-20-046988 · doc4.xml · nonDerivative · entry 4 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,366 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and includes the sale of shares in order to cover tax liabilities in connection with the vesting of restricted stock units and the exercise of stock options. F4 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $43.98 to $44.92. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 19:06 UTC | Anterix Inc. ATEX · Entity 4597 | Exercise / conversionCommon Stock | 8,808 | $20.00 | $176,160.00 |
DisclosureSEC source: 0001209191-20-046988 · doc4.xml · nonDerivative · entry 3 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 19:06 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 200 | $44.93 | $8,985.00 |
DisclosureSEC source: 0001209191-20-046988 · doc4.xml · nonDerivative · entry 2 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,130 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and includes the sale of shares in order to cover tax liabilities in connection with the vesting of restricted stock units and the exercise of stock options. F3 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $44.92 to $44.93. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 19:06 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 7,835 | $44.48 | $348,477.30 |
DisclosureSEC source: 0001209191-20-046988 · doc4.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,330 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and includes the sale of shares in order to cover tax liabilities in connection with the vesting of restricted stock units and the exercise of stock options. F2 · price: This transaction was executed in multiple sales through a sale order executed by a broker-dealer at prices ranging from $43.90 to $44.90. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 19:18 UTC | Anterix Inc. ATEX · Entity 4597 | GrantCommon Stock | 40,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039181 · doc4.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,165 F1 · shares: Represents the issuance of restricted stock units (the "RSUs"). The RSUs will vest in full on July 1, 2021. Read SEC document |
| May 26, 2020 Filed May 28, 2020 18:23 UTC | Anterix Inc. ATEX · Entity 4597 | GrantCommon Stock | 4,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032708 · doc4.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,100 F1 · shares: Represents the issuance of restricted stock units (the "RSUs") in lieu of a cash bonus payment the Recipient was eligible to receive pursuant to the Issuer's Short-Term Incentive Plan for services performed by the Recipient during the fiscal year ended March 31, 2020. The Issuer's Compensation Committee issued the RSUs in lieu of the cash bonus payment to help conserve the Issuer's cash resources. Read SEC document |
| October 16, 2019 Filed Apr 7, 2020 19:58 UTC | Anterix Inc. ATEX · Entity 4597 | GiftCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023882 · doc5.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,901 F1 · kind: These transactions represent gifts or charitable contributions by the Reporting Person. Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 17:35 UTC | Anterix Inc. ATEX · Entity 4597 | Tax withholdingCommon Stock | 2,365 | $41.99 | $99,306.35 |
DisclosureSEC source: 0001209191-19-046845 · doc4.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,401 F1 · shares: The shares were withheld by the Issuer to satisfy tax withholding obligations in connection with the partial vesting and settlement of restricted stock units granted August 2018. Read SEC document |
| May 09, 2019 Filed May 10, 2019 19:04 UTC | Anterix Inc. PDVW · Entity 4597 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029110 · doc4.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,766 F1 · shares: Represents the issuance of restricted stock units (the "RSUs"). 25% of the RSUs vest and become exercisable on May 15, 2020 with the remaining shares vesting in 3 equal annual installments thereafter. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 17:16 UTC | Anterix Inc. PDVW · Entity 4597 | GrantCommon Stock | 20,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045863 · doc4.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Vice Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,266 F1 · shares: Represents the issuance of restricted stock units (the "RSUs"). 25% of the RSUs vest and become exercisable on August 6, 2019 with the remaining shares vesting in 3 equal annual installments thereafter. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:47 UTC | Anterix Inc. PDVW · Entity 4597 | Tax withholdingCommon Stock | 3,142 | $30.05 | $94,417.10 |
DisclosureSEC source: 0001209191-17-060450 · doc4.xml · nonDerivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Vice Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,292 F1 · shares: The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting and settlement of restricted stock units granted May 2014. Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:52 UTC | Anterix Inc. PDVW · Entity 4597 | GrantStock Option (Right to Buy) · Derivative | 54,945 | $0.00 Strike: $22.75 | $0.00 |
DisclosureSEC source: 0001209191-17-035180 · doc4.xml · derivative · entry 1 OBRIEN MORGAN E · CIK 0000937846 · Director · Vice Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,945 Underlying: Common Stock · 54,945 shares Expires 2027-05-22 F1 · derivative.exercise_date: 25% of the option shares vest and become exercisable on May 22, 2018 with the remaining shares vesting in 3 equal annual installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.